A key point for successful transplantation of autologous hematopoietic stem cells in the treatment of leukemia is the purging technique, of which photodynamic therapy (PDT) proved effective and promising. The aim of this study was to evaluate the purging effect of a novel amphipathic photosensitizer, di-sulfo-di-phthalimidomethyl phthalolcyanine zinc (ZnPcS 2 P 2 )-based PDT (ZnPcS 2 P 2 -PDT) on murine erythroblastic leukemic EL9611 cells. Bone marrow cells (BMC), harvested from normal BALB/c mice, were contaminated with variable EL9611 cells. Cell suspensions were incubated with 4 lg/ml ZnPcS 2 P 2 for 5 h and then exposed to 2.1 J/cm 2 irradiation by a semiconductor laser 670 nm. Lethally irradiated recipient BALB/c mice (7 Gy) received syngeneic bone marrow transplantation with purged or nonpurged cell mixtures of 10 7 BMC contaminated with variable numbers (10 2 -10 5 ) of EL9611 cells. All of the irradiated controls died due to sepsis. All of the mice injected with nonpurged cell mixtures developed leukemia and died, whereas the mice transplanted with ZnPcS 2 P 2 -PDT-treated mixtures had a longer survival time, and the fewer leukemic cells there were in the cell mixtures, the higher the leukemia-free survival rate. We conclude that ZnPcS 2 P 2 -PDT could purge leukemic cells from bone marrow autografts but could retain sufficient progenitor cells for the hematopoietic activity.
Introduction
High-dose chemotherapy supported by hematopoietic stem cell transplantation (HSCT) offers an effective access to cure of leukemia. Autologous HSCT (Auto-HSCT) enjoys several advantages over allogeneic HSCT (Allo-HSCT): easy transplantation of grafts, without the restriction of age and the need for an HLA-matched donor, the absence of graft-versus-host disease (GVHD) and a small percentage of life-threatening infections. [1] [2] [3] [4] It has been proven that auto-HSCT is a promising approach for leukemia therapy. However, it still has its limitation of high relapse rate, as compared with Allo-HSCT and the limitation is ascribed to the risk of reinfusing residual leukemic cells at the time of harvest. [5] [6] [7] Several studies on animals have indicated that it is necessary to purge leukemic cells from the bone marrow ex vivo prior to transplantation. [8] [9] [10] [11] [12] Therefore, it is essential to eradicate selectively the leukemic cells from grafts for the application of auto-HSCT in leukemia.
There are some techniques such as pharmacological purging and immunotoxins that have been employed to purge remission marrow of residual leukemic cells. However, these attempts have been hindered due to the nonspecific cytotoxicity of chemotherapeutic agents such as 4-hydroperoxycyclophosphamide and the lack of monoclonal antibodies to well characterized leukemia antigens. Photodynamic therapy (PDT), widely studied for its anticancer activity, relies on a bimodal protocol comprised of chemical-photosensitization and light-irradiation. The two components are nontoxic individually but tumoricidal in combination. Through the generation of reactive oxygen species (ROS), especially singlet oxygen, PDT affects various aspects of cell biology, which subsequently results in the killing of cancerous cells. [13] [14] [15] Several researchers have reported that human leukemic cell lines exhibit greater photosensitizer uptake and higher susceptibility to PDT than do the normal bone marrow cells (BMC). [16] [17] [18] [19] [20] [21] Photosensitizer is a key factor for PDT. A novel amphipathic photosensitizer, di-sulfo-di-phthalimidomethyl phthalolcyanine zinc, ZnPcS 2 P 2 (developed in China) was employed in the present study. According to previous studies, 22 ZnPcS 2 P 2 enjoys some advantages over conventional photosensitizers such as hematoporphyrin derivatives or other porphyrin derivatives. Our previous study 21 demonstrated for the first time that leukemic cell lines exhibited higher susceptibility to ZnPcS 2 P 2 -based PDT (ZnPcS 2 P 2 -PDT) than normal hematopoietic cells and ZnPcS 2 P 2 -PDT could eliminate the residual K562 cells in the simulated remission bone marrow. However, it does not follow that the survival of normal progenitors may ensure a hematopoietic reconstitution of the purged BM and that the clonogenic leukemic cells may parallel leukemic stem cells. Therefore, in the present study, we probed into the purging effects of ZnPcS 2 P 2 -PDT on murine erythroblastic leukemia EL9611 cells in mouse model. In ZnPcS 2 P 2 , the number ratio of the hydrophilic group (S group) and lipophilic group (P group) is 2:2. These two groups are cis arrangement in ZnPcS 2 P 2 molecule. In addition, the oxygen atom of P group can provide a site to form hydrogen bond with the oxygen atom of low-density lipoprotein that is easy to be enriched in tumor tissue. The amphipathic structure of ZnPcS 2 P 2 results in the selective uptake of sensitizer by tumor cells. ZnPcS 2 P 2 was dissolved in a solution comprised of Cremophor EL 2%(V/V), propylene glycol 20% (V/V), NaCl 0.9%(W/W) to make a 620 mg/ml stock solution and stored in the dark at 41C.
Materials and methods

Photosensitizer
Mice
Female BALB/c mice, 5-6 weeks old, were purchased from the Shanghai Experimental Animal Center (Institute of Chinese Academic Medical Science, China) and housed in a specific pathogen-free animal facility. From 1 week before engraftment to 4 weeks after transplantation, antibiotics (tetracycline and neomycin) were added to the recipient animals' drinking water to reduce the mortality that usually occurred secondary to infections during the early recovery period.
Leukemic cell line 7,12-DMBA-induced erythroblastic leukemic EL9611 cells were maintained via serial passage of spleen cell suspensions. 23 The cells were obtained from the State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Science, Tianjin, China. Intravenous (i.v.) inoculations of 10 2 or more viable cells into BALB/c mice resulted in progressive growth of leukemia with 100% incidence but without spontaneous remission. When BALB/c mice were injected i.v. with leukemic cells varying from 1 Â 10 2 to 1 Â 10 6 , there was an inverse linear between the logarithm of leukemic cells infused and the medium survival of the mice. There were a large number of leukemic cells in the peripheral blood and most of them were early normoblasts or polychromatic normoblasts. Infiltration of leukemic cells involved mainly the bone marrow, the spleen and the liver. There was no obvious infiltration of leukemic cells in lymph nodes, thymus or other tissues. The spleens of moribund erythroblastic leukemic mice were dissected under sterile conditions, homogenized in RPMI 1640 (GIBCO BRL, USA) and passed through a wire mesh to create single EL9611 cell suspensions. The cells were counted for total number and viability was determined by Trypan Blue dye exclusion.
Isolation of bone marrow
Syngeneic BALB/c mice were killed by cervical dislocation under anesthesia. BMC were collected from the long bones (femur, tibia) of the donor mice. The bones were kept in ice-cold RPMI 1640 and the marrow was flushed out twice with the medium. The collected marrow was filtered through sterile gauze, spun down, and washed twice in RPMI 1640. The cells were then re-suspended and counted for total number, and viability was determined by Trypan Blue dye exclusion.
Total body irradiation (TBI)
The recipient BALB/C mice were irradiated at a dose rate of 15cGy/min, reaching a total dose of 7 Gy from a 60 Co g source. The TBI dose was lethal, for all irradiated control BALB/c mice died of marrow aplasia within 13 days.
Purging procedure 5 Â 10 6 /ml mouse BMC or BMC mixed with various number of EL9611 cells (ranging from 50 to 5 Â 10 4 /ml) were untreated or treated with the purging procedure. The procedure was as follows: the cell suspensions were incubated with 4 mg/ml ZnPcS 2 P 2 for 5 h and then photoirradiated by a LD-670 semiconductor laser (Institute of Laser, Tianjin, China) emitting red light at 670 nm. The light was delivered via a quartz fiber microlens delivery system, and measured by a TPM 310 power meter (Lexel, USA). The power density at the illumination area was 53 mW/cm 2 and total light dose was 2.1 J/cm 2 . The cell suspensions were then washed twice and suspended in RPMI 1640 medium of the same volume as origin to establish 10-fold concentrated suspensions. In order to obtain comparable results, purged or nonpurged cell suspensions were spun down and resuspended in the medium of a 10% volume as origin to establish 10-fold concentrated suspensions and 0.2 ml of nonpurged cell suspensions contained 1 Â 10 7 BMC. Cell suspensions in 0.2 ml final volume were injected into the lateral tail vein of BALB/c recipients 4 h post irradiation, irrespective of the surviving cell count.
Mouse survival studies Mice were monitored daily for survival of 180 days and white blood cells were counted twice a week. Mice that were observed to be terminally ill were sacrificed. Necropsy was performed routinely, and the weights of spleens and livers were determined. Histological study of bone marrow, spleens and livers were carried out.
Statistical analysis
The differences of survival period between different groups of mice were assessed by the log-rank test.
Results
Experiments were performed to determine if infusion of BMC/EL9611 cells mixtures purged by ZnPcS 2 P 2 -PDT could prolong the survival time of irradiated recipient mice. All 16 irradiation controls that received 7 Gy TBI without subsequent marrow infusion died of bone marrow aplasia between days 10 and 13. As was confirmed by histology, all the mice suffered from sepsis with multiple necrotic areas in the atrophic livers and spleens. However, all eight recipients receiving ZnPcS 2 P 2 -PDT-treated BMC survived longer than 180 days, which indicates that the BM stem cells are capable of reconstituting the hematopoietic system after the purging was performed.
To establish the relationship between the number of viable leukemia cells transplanted and the survival time of the recipient mice, each irradiated mouse received untreated 1 Â 10 7 BMC contaminated with viable EL9611 cells ranging from 1 Â 10 2 to 1 Â 10
5
. All recipients died of leukemia and displayed massive hepatosplenomegaly at necropsy. The mean weights of livers and spleens in mice suffering from leukemia were significantly greater than those of the TBI controls, with liver weights of 1.6770.11 vs 0.4870.03 g (Po0.001) and spleen weights of 0.2370.03 vs 0.0270.01 g (Po0.001). A subsequent histological assessment confirmed widespread leukemia infiltration in both organs. The individual survival time is plotted in Figure 1 . A decrease of survival time was observed with higher numbers of leukemia cells in the mixture. In the range tested, there was an inverse linear relationship (r 2 ¼ 0.96) between the logarithm of leukemia cells infused and the medium survival time of the mice. Furthermore, the longer the mice survived, the greater the numbers of platelets, of red blood cells and of normal white blood cells found in the peripheral blood. The results demonstrated progressive hematopoietic recovery after the transplantation. Table 1 
Discussion
In patients with complete remission, there might still be a burden of 1 Â 10 8 leukemia cells in autografts and therefore purging grafts should be accomplished with a protocol capable of killing leukemic cells of four logs for auto-HSCT. Furthermore, the feasibility of a purging modality can be deduced from the ratio of the surviving fractions between normal and leukemic cells. Given the selective propensity of PDT, a number of research groups, including ours, have proven the efficacy of PDT on the purging of hematopoietic grafts contaminated with leukemic cells. [16] [17] [18] [19] [20] [21] Studies so far were mainly focused on the determination of the residual amount of hematopoietic progenitor subsets that are only responsible for short-term engraftment, but the primitive hematopoietic stem cells are a relevant subset to reconstitute hematopoiesis. Therefore, a more reliable assay system for the survival of stem cells in a purged bone marrow is the long-term survival of irradiated, transplanted mice. 24 The current study offers for the first time an in vivo demonstration of the efficacy of PDT on the purging of grafts contaminated with leukemic cells in mice model.
The intracellular concentrations of photosensitizers were important factors in the effectiveness of PDT. 25 Therefore, PDT requires essentially high contrast between malignant cells and surrounding normal cells as well as sufficient concentration of photosensitizer in malignant cells. On the basis of our previous studies, there were different kinetic changes of ZnPcS 2 P 2 concentration between leukemic cell lines and normal BMC. 21 After 5 h incubation with ZnPcS 2 P 2 , the ratio of the photosensitizer content in leukemic cell lines and that in normal BMC reached its peak. The content of ZnPcS 2 P 2 was high in leukemic cells but low in BMC. Therefore, cell suspensions were harvested and irradiated sharply after the 5 h incubation with ZnPcS 2 P 2 . Under these conditions, ZnPcS 2 P 2 -PDT could photoinactivate leukemic cells selectively and eliminate the residual K562 leukemic cells in BMC. 21 So in this study, the process was performed under the identical situation. The effects of ZnPcS 2 P 2 -PDT on normal murine hematopoietic stem cells in bone marrow were compared with those on murine erythroblastic leukemic EL9611 cells to determine whether ZnPcS 2 P 2 -PDT provides an effective purging protocol.
It is well known that in inbred animals, the probability of homozygosity in any gene localization is 99%, and each inbred animal bears the same hereditary constitution and characteristics. Each individual inbred animal bears identical histocompatibility antigens and no rejections occur after allogeneic transplantation. Therefore, we regarded the bone marrow transplantation of syngeneic BALB/c mice as the model of autogenous transplantation. We used lethally irradiated mice as recipients, given that the objective of the study was to probe into the purging effects of ZnPcS 2 P 2 -PDT on the depletion of residual EL9611 cells in simulated remission bone marrow grafts in mice and exclude leukemia relapse because of the residual EL9611 cells in the body.
Complete cure was achieved in mice infused with ZnPcS 2 P 2 -PDT-purged BMC/EL9611 cells whereas 100% incidence of leukemia occurred in all the control receiving nonpurged cell mixtures. The findings imply that ZnPcS 2 P 2 -PDT retained sufficient hematopoietic progenitors to allow complete hematopoietic reconstitution to overcome aplasia in the early phase after lethal irradiation, and killed sufficient EL9611 cells to restrain leukemia incidence. The fewer EL9611 cells contaminated the grafts, the higher the leukemia-free survival rate.
In conclusion, ZnPcS 2 P 2 -PDT appears to be a promising purging strategy for bone marrow grafts. To the best of our knowledge, this is the first report that determines the purging potency of PDT in murine model.
